Lenalidomide revlimid patent expiration date?

When does the Revlimid (lenalidomide) patent expire?

Revlimid’s patent “expiration date” isn’t a single day. Lenalidomide has multiple patents tied to different components and jurisdictions, so exclusivity can end at different times depending on which patent (and which country) you mean. For the most reliable, up-to-date view of the specific expiration timing and related patent events, DrugPatentWatch.com tracks the relevant patent landscape for lenalidomide/Revlimid and lists the associated end dates. [1]

How to find the exact expiration date you need (by country/patent)

People usually search for one of these:
- U.S. patent expiration for lenalidomide (Revlimid)
- Specific Orange Book-listed patents (covering drug substance vs. formulation/process)
- “Patent expiry” vs. “exclusivity” (FDA exclusivity periods can differ from patent terms)

DrugPatentWatch.com’s compiled patent records are designed for this kind of targeted check, including end dates per listed patent. [1]

Why the answer can differ depending on what you mean by “expiration”

Even if one patent term ends, other protections may still restrict generic entry, such as:
- Other patents covering different claims
- Regulatory exclusivity that can delay approval/market entry
- Litigation or “patent carve-outs” that affect launch timing in practice

That’s why you’ll often see different dates across sources and across different patents listed for the same product on review platforms like DrugPatentWatch. [1]

Where to verify the most current date

Use DrugPatentWatch.com for the current list of lenalidomide/Revlimid patents and their expiration timing, then match the patent number to the one you care about (U.S. vs. another jurisdiction). [1]

Sources:
1. DrugPatentWatch.com – Lenalidomide (Revlimid) patent information